| 2019 £m | 2018 £m | |
|---|---|---|
| Deferred consideration – less than one year | – | 1.8 |
| Deferred consideration – more than one year | – | – |
| – | 1.8 | |
| Contingent consideration – less than one year | 5.1 | 7.0 |
| Contingent consideration – more than one year | 30.9 | 28.0 |
| 36.0 | 35.0 | |
| 36.0 | 36.8 |
The consideration for certain acquisitions and licensing agreements includes amounts contingent on future events such as development milestones or sales performance. The Group has provided for the fair value of this contingent consideration as follows:
| Tri-Solfen® | StrixNB® & DispersinB® | Injectable Solution 1 | Injectable Solution 2 | Phycox® | Other | Total | |
|---|---|---|---|---|---|---|---|
| As at 1 July 2017 | 25.5 | 3.6 | – | – | 3.1 | 0.5 | 32.7 |
| Additions | – | – | 6.5 | – | – | 2.4 | 8.9 |
| Remeasurement through intangibles | (0.9) | (2.2) | – | – | – | – | (3.1) |
| Remeasurement through income statement | – | (0.1) | – | – | – | – | (0.1) |
| Cash payments: investing activities | – | – | – | – | (0.6) | (1.1) | (1.7) |
| Finance expense | – | – | – | – | 0.4 | 0.2 | 0.6 |
| Foreign exchange adjustments | (1.8) | (0.2) | 0.1 | – | (0.1) | – | (2.0) |
| Other movements | – | – | – | – | – | (0.3) | (0.3) |
| At 30 June 2018 | 22.8 | 1.1 | 6.6 | – | 2.8 | 1.7 | 35.0 |
| Additions | – | – | – | 7.9 | – | – | 7.9 |
| Remeasurement through intangibles | (1.0) | (0.3) | (0.3) | – | – | 0.1 | (1.5) |
| Remeasurement through income statement | – | (0.1) | – | – | – | – | (0.1) |
| Cash payments: investing activities | – | (0.1) | (2.1) | (3.0) | (0.7) | (0.4) | (6.3) |
| Finance expense | 0.6 | 0.1 | 0.2 | – | 0.1 | – | 1.0 |
| Foreign exchange adjustments | (0.4) | – | – | 0.3 | – | 0.1 | – |
| Other movements | – | – | – | – | – | – | – |
| At 30 June 2019 | 22.0 | 0.7 | 4.4 | 5.2 | 2.2 | 1.5 | 36.0 |
The consideration payable for Tri-Solfen® is expected to be payable over a number of years, and relates to development milestones and sales performance. During the year, the development milestones have been remeasured and consequently are now expected to happen later than initially anticipated. A delay in the timing of contingent cash flows of one year would result in a decrease of the liability and intangible asset of £3.5 million. An increase in the discount rate by 1% would result in a decrease of the deferred consideration and associated intangible of £1.1 million.
The consideration payable for StrixNB® and DispersinB® is expected to be payable over a number of years, and relates to development milestones and sales performance. During the year the contingent consideration has been remeasured and consequently one of the development milestones is no longer expected to be achieved. To the extent possible this has been remeasured through intangibles with the excess being credited to the income statement, and treated as non-underlying.
The consideration for two separate licensing agreements for injectable solutions both relate to development milestones, and Phycox relates to sales performance. The consideration payable is expected to be payable for these agreements within the next five years.
Where a liability is expected to be payable over a number of years the total estimated liability is discounted to its present value.